Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prelude Therapeutics Incorporated filings document the formal disclosures of a clinical-stage precision oncology company developing targeted cancer therapies. Recent 8-K reports cover Regulation FD materials, financial results, FDA and IND-related updates for PRT12396, preclinical data for PRT13722, and investor presentation materials.
The company’s SEC record also includes proxy disclosures on board matters, shareholder voting, executive compensation, and equity awards. Capital-structure filings describe Prelude’s Nasdaq-listed common stock, shelf registration and prospectus supplement activity, and at-the-market equity sales arrangements, while other material-event reports document leadership appointments and related employment and compensation arrangements.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Prelude Therapeutics Inc reported a routine compensation grant involving its board representative from Baker Bros. Advisors. Dr. Paul C. Scherer, who serves on the board, received a grant of 38,000 non-qualified stock options exercisable into common stock at a strike price of $3.94 per share. The options vest on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual stockholder meeting, and expire on June 8, 2036. The filing explains that, under Baker Bros. Advisors’ policies, Dr. Scherer has no personal right to these securities; instead, affiliated funds, including 667, L.P. and Baker Brothers Life Sciences LP, hold an indirect proportionate pecuniary interest, while Baker Bros. Advisors retains voting and dispositive power. Julian and Felix Baker may be deemed to have only an indirect pecuniary interest through their ownership interests in the related entities and expressly disclaim broader beneficial ownership.
Prelude Therapeutics Inc reported that director Katina Dorton received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Dorton continues providing service to the company through the vesting date. Following this grant, she holds options for 38,000 shares directly.
Prelude Therapeutics Inc director Martin Babler received a grant of options to buy 38,000 shares of common stock as compensation. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to his continued service. Following this grant, Babler directly holds options for 38,000 underlying common shares.
Prelude Therapeutics Inc director David P. Bonita received a grant of stock options covering 38,000 shares of Common Stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036. The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to continued service. Under an agreement, any securities or economic benefit from these options are required to be transferred to OrbiMed-related entities.
Prelude Therapeutics Inc director Sandor Victor received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest upon the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Victor continues providing service through the applicable vesting date. After this grant, he holds options for 38,000 shares directly.
Prelude Therapeutics Inc director Paul A. Friedman received a grant of stock options as part of his board compensation. The award covers 38,000 options to buy common stock at an exercise price of $3.94 per share and expires on June 8, 2036. The options will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided he continues serving the company through the vesting date.
Prelude Therapeutics Incorporated reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class III directors—Krishna Vaddi, Paul Scherer, and Katina Dorton—to terms expiring at the 2029 annual meeting, each receiving over 25 million votes in favor.
Investors also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 31,841,080 shares voting for and minimal opposition. In advisory votes, stockholders approved 2025 executive compensation and indicated a preference to hold say-on-pay votes every one year.
Prelude Therapeutics reported a significantly smaller net loss of $10.4 million for the quarter ended March 31, 2026, compared with $32.1 million a year earlier. The improvement was driven by recognizing $4.6 million of collaboration revenue from its Exclusive Option Agreement with Incyte and sharply lower research and development spending.
R&D expense fell to $13.6 million from $28.8 million, mainly after pausing SMARCA2 clinical programs and reducing internal costs, while general and administrative expense edged down to $5.2 million. Prelude ended the quarter with $84.8 million in cash, cash equivalents, restricted cash and marketable securities, and subsequently raised an estimated $85.5 million of net proceeds in an April equity and pre‑funded warrant offering, extending its liquidity.
Prelude Therapeutics filed an 8-K reporting first quarter 2026 results and a broad R&D update. Revenue reached $4.58 million for the three months ended March 31, 2026, compared with none in the prior-year period, while net loss narrowed to $10.4 million, or $0.13 per share, from $32.1 million, or $0.42 per share.
Research and development expense fell to $13.6 million from $28.8 million, largely due to pausing SMARCA2 trials, and general and administrative expense declined to $5.2 million. Cash, cash equivalents, restricted cash and marketable securities totaled $84.8 million as of March 31, 2026, and an underwritten offering afterward added about $90 million, supporting a projected cash runway into the second quarter of 2028. Operationally, Prelude began enrolling a Phase 1 study of JAK2V617F inhibitor PRT12396 in polycythemia vera and myelofibrosis, plans an IND filing by mid-2026 and Phase 1 start in the second half of 2026 for KAT6A degrader PRT13722, continues discovery work on mCALR-directed degrader antibody conjugates, and appointed Charles Morris, M.D. as Chief Medical Officer.
Prelude Therapeutics Inc reported that Chief Medical Officer Charles Q. Morris received an employee stock option grant covering 450,000 shares of common stock at an exercise price of $4.70 per share.
The option vests 25% on May 1, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service. The option expires on April 30, 2036, and all 450,000 options are reported as held directly following this grant.